The dose-dependent antiangiogenic potential of apixaban: an experimental outlook
Aim: Direct oral anticoagulants (DOACs) are good alternatives to conventional medical regimens for the treatment and prevention of thromboembolism. Apixaban is one of the more popular variations of these newly developed drugs. Aside from its anticoagulant potential, possible cellular effects remain...
Saved in:
| Main Authors: | Özgür Akkaya, Eyüp Aydoğan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Alanya Alaaddin Keykubat University
2022-08-01
|
| Series: | Acta Medica Alanya |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/2483234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and Validation of an HPLC-MS/MS Method for Quantification of Apixaban in Human Plasma
by: U. D. Filonova, et al.
Published: (2024-03-01) -
Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting
by: Rupesh Subash, et al.
Published: (2025-05-01) -
Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022
by: A. V. Matveev, et al.
Published: (2024-01-01) -
Apixaban failure in a post-bariatric surgery female patient with thoracic aortic thrombus secondary to COVID-19
by: Joshua Hermiz, et al.
Published: (2025-03-01) -
Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023-01-01)